Delving into the Latest Updates on Fondazione Matilde Tettamanti e Menotti de March with Synapse

概览

疾病领域	数量

血液及淋巴系统疾病	1
免疫系统疾病	1
肿瘤	1

排名前五的药物类型	数量

CAR-T	1

排名前五的靶点	数量

CD19 x IL18R1	1

关联

1

项与 Fondazione Matilde Tettamanti e Menotti de March 相关的药物

CIK-CAR CD19 immunotherapy (CoImmune)

靶点

CD19 x IL18R1

作用机制

CD19抑制剂 [+1]

在研机构

Formula Pharmaceuticals, Inc. [+1]

原研机构

University of Milano-Bicocca

在研适应症

难治性B细胞淋巴瘤 [+5]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

1

项与 Fondazione Matilde Tettamanti e Menotti de March 相关的临床试验

NCT03389035 / Completed临床1/2期IIT

Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation

This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

开始日期2017-12-20

申办/合作机构

Fondazione Matilde Tettamanti e Menotti de March

100 项与 Fondazione Matilde Tettamanti e Menotti de March 相关的临床结果

登录后查看更多信息

0 项与 Fondazione Matilde Tettamanti e Menotti de March 相关的专利（医药）

登录后查看更多信息

100 项与 Fondazione Matilde Tettamanti e Menotti de March 相关的药物交易

登录后查看更多信息

100 项与 Fondazione Matilde Tettamanti e Menotti de March 相关的转化医学

登录后查看更多信息